Released May 14, 2026, after the close
10-Q filed May 14, 2026, 44 days after period end · 0001213900-26-056651
Q1 2026 · 10-Q
Revenue—
Net Income$4.34M$4.34M N/M vs Q1 2025+0.2% vs Q4 2025
EPS, diluted—
Operating Income-$132,030N/M
Operating Cash Flow-$102,503N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Income | $4.34M | -$59.33K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Drugs Made In America Acquisition II Corp. · CIK 2040475 · Engraved from SEC EDGAR